Multi-systemic diseases such as amyloidosis are not only complex to diagnose, but also complex in the treatment and ongoing patient care. It takes a village. In this seminal piece, the American College of Cardiology (ACC) provides an Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. An absolute must-read for cardiologists and other specialties such as neurology, gastroenterology, nephrology and hematology.
heart failure
Hereditary Amyloidosis: The V122I Variant
Despite the evidence that a meaningful 3-4% of the US Black population of West African ancestry likely carries the V122I genetic mutation, hereditary TTR amyloidosis remains significantly underdiagnosed and undertreated in this population. Amyloidosis can be devastating to both patients and their families. Increased awareness of the disease, availability of testing, and FDA-approved therapies are slowly beginning to shift this dynamic. However, there is still much work to be done to close the gap between diagnosed cases and the population estimated to be affected.
Heart Failure & Amyloidosis
Heart failure occurs when the heart muscle doesn’t pump blood as well as it should. Many medical conditions that damage the heart muscle can cause heart failure, such as Coronary artery disease, Heart attack, Obesity, Kidney disease, Diabetes, and Cardiomyopathy. Here we summarize how cardiac amyloidosis is associated with heart failure.
Cardiomyopathy & Amyloidosis
Cardiomyopathy is a broad term that is used to describe disease of the heart muscle, making it difficult for the heart to provide the body with an adequate blood supply. It can lead to heart failure and even death. In this article, we’ll discuss the types of cardiomyopathy and its connection to amyloidosis.
